PrimeRFP SCOUT · Federal Contract Recompete Brief

W911SR22F0014Clinical development PHASE 2 STUDY — Ology Bioservices, Inc

Ology Bioservices, Inc holds $17.4M across 7 federal awards, concentrated at Department of Defense (DOD). This PIID sits alongside 2 related awards under parent W911SR22D0009. Recompete timing centers on the Feb 29, 2028 PoP end — agencies typically plan 12–18 months ahead.

W6qk Acc-Apg

Awarding office

Ology Bioservices, Inc

Recipient

Feb 29, 2028

PoP end

$93M

Obligated

541715

NAICS

AN42

PSC

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Ology Bioservices, Inc — $90

Contract facts

Federal

Contract numberW911SR22F0014

Also listed asW911SR-22-F-0014

Also listed asW911SR22D0009-W911SR22F0014

AgencyW6qk Acc-Apg

Awarding officeW6qk Acc-Apg

IncumbentOlogy Bioservices, Inc

UEIGC2RFAZK8G64

NAICS541715

PSCAN42

Parent IDIQ / IDVW911SR22D0009

Place of performanceFREDERICK, MD

Related solicitationW911SR22R0040

PoP end (current)Feb 29, 2028

Obligated$93M

CLINICAL DEVELOPMENT PHASE 2 STUDY is a federal award for W6qk Acc-Apg held by Ology Bioservices, Inc. Estimated value $107.9M ($93M obligated). Current period of performance ends Feb 29, 2028. Place of performance: FREDERICK, MD. Related solicitation W911SR22R0040.

Recompete timing

Public

● Expiring in 558 days

Current PoP ends Feb 29, 2028 (558 days remaining). Agencies typically plan 12–18 months ahead — capture window opens around Aug 29, 2026.

Incumbent footprint

Public record

Ology Bioservices, Inc — $17.4M obligated across 7 awards (firm-wide, all agencies) · lead buyer Department of Defense (DOD).

% of firm-wide obligated ($17.4M) · all agencies

Department of Defense (DOD)$11.6M · 67%Department of Health and Human Services (HHS)$5.8M · 33%

Related awards

Same parent · incumbent

W911SR23F0057

DRUG SUBSTANCE (DS) PROCESS VALIDATION, DRUG PRODUCT (DP) PROCESS VALIDATION, CLINICAL DEV…

Department of Defense (DOD) · OLOGY BIOSERVICES, INC.

$67.6M

Jan 5, 2028

W911SR22F0073

DS PROCESS CHARACTERIZATION

Department of Defense (DOD) · OLOGY BIOSERVICES, INC.

$10.8M

Jan 5, 2028

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract W911SR22F0014?

W911SR22F0014 (Clinical development PHASE 2 STUDY) is a W6qk Acc-Apg award with an estimated value of $107.9M, currently held by Ology Bioservices, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

What is W911SR-22-F-0014?

W911SR-22-F-0014 is the dashed form of PIID W911SR22F0014 (Clinical development PHASE 2 STUDY), held by Ology Bioservices, Inc. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.

Which office awarded W911SR22F0014?

W6qk Acc-Apg awarded W911SR22F0014 to Ology Bioservices, Inc.

Who is the incumbent on W911SR22F0014?

Ology Bioservices, Inc is the incumbent with $17.4M across 7 related awards in SCOUT’s public footprint. The current period of performance ends Feb 29, 2028.

When does Ology Bioservices, Inc’s W911SR22F0014 come up for recompete?

SCOUT tracks a period-of-performance end of Feb 29, 2028. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Aug 20, 2026 · refreshed monthlyLatest procurement action Jan 14, 2026